The 7 major hemophilia B markets reached a value of US$ 9.2 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 22.5 Billion by 2034, exhibiting a growth rate (CAGR) of 10.45% during 2023-2034.
The hemophilia B market has been comprehensively analyzed in this report titled "Hemophilia B Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemophilia B refers to a rare genetic bleeding disorder that impairs the blood's ability to clot properly. This disease is inherited in an X-linked recessive manner and typically affects males, while females are usually carriers of the condition. Individuals suffering from hemophilia B have low levels or a complete absence of a protein called factor IX, leading to prolonged and excessive bleeding, even from minor injuries or spontaneously. The common symptoms associated with this ailment include easy and severe bruising, frequent nosebleeds, joint pain or swelling, irritability, stiff neck, vomiting, seizures, breathing difficulties, mental status changes, prolonged bleeding after cuts or surgery, etc. The diagnosis of the illness is typically made through a detailed medical history, a physical exam, and a complete blood count analysis. A healthcare provider may perform several coagulation studies, like activated partial thromboplastin time, factor IX assay, fibrinogen test, etc., to evaluate the clotting function and severity of the disease in patients. Additionally, genetic testing is recommended to identify the specific mutation that is causing the underlying indication.
The rising cases of inherited diseases, resulting in variations in the gene that provides instructions for producing specific proteins within the body, are primarily driving the hemophilia B market. Moreover, the widespread adoption of factor replacement therapy, owing to its numerous advantages, such as preventing severe blood loss and improving the quality of life, is further creating a positive outlook for the market. Besides this, the emerging popularity of topical fibrin sealants for treating patients since they can be applied directly to wounds or bleeding sites to promote clot formation and control hemorrhage is acting as another significant growth-inducing factor. Furthermore, several key players are making extensive investments in R&D activities to launch non-replacement therapies that enhance the body's natural clotting processes and reduce bleeding episodes. This, in turn, is also bolstering the market growth. Additionally, the escalating utilization of gene therapy, which involves introducing a functional copy of the faulty gene into the patient's cells, thereby encouraging the production of factor IX in the body, is expected to drive the hemophilia B market in the coming years.
This report provides an exhaustive analysis of the hemophilia B market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemophilia B and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemophilia B market in any manner.
The hemophilia B market has been comprehensively analyzed in this report titled "Hemophilia B Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemophilia B refers to a rare genetic bleeding disorder that impairs the blood's ability to clot properly. This disease is inherited in an X-linked recessive manner and typically affects males, while females are usually carriers of the condition. Individuals suffering from hemophilia B have low levels or a complete absence of a protein called factor IX, leading to prolonged and excessive bleeding, even from minor injuries or spontaneously. The common symptoms associated with this ailment include easy and severe bruising, frequent nosebleeds, joint pain or swelling, irritability, stiff neck, vomiting, seizures, breathing difficulties, mental status changes, prolonged bleeding after cuts or surgery, etc. The diagnosis of the illness is typically made through a detailed medical history, a physical exam, and a complete blood count analysis. A healthcare provider may perform several coagulation studies, like activated partial thromboplastin time, factor IX assay, fibrinogen test, etc., to evaluate the clotting function and severity of the disease in patients. Additionally, genetic testing is recommended to identify the specific mutation that is causing the underlying indication.
The rising cases of inherited diseases, resulting in variations in the gene that provides instructions for producing specific proteins within the body, are primarily driving the hemophilia B market. Moreover, the widespread adoption of factor replacement therapy, owing to its numerous advantages, such as preventing severe blood loss and improving the quality of life, is further creating a positive outlook for the market. Besides this, the emerging popularity of topical fibrin sealants for treating patients since they can be applied directly to wounds or bleeding sites to promote clot formation and control hemorrhage is acting as another significant growth-inducing factor. Furthermore, several key players are making extensive investments in R&D activities to launch non-replacement therapies that enhance the body's natural clotting processes and reduce bleeding episodes. This, in turn, is also bolstering the market growth. Additionally, the escalating utilization of gene therapy, which involves introducing a functional copy of the faulty gene into the patient's cells, thereby encouraging the production of factor IX in the body, is expected to drive the hemophilia B market in the coming years.
This report provides an exhaustive analysis of the hemophilia B market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemophilia B and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemophilia B market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the hemophilia B market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the hemophilia B market
Competitive Landscape:
This report also provides a detailed analysis of the current hemophilia B marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the hemophilia B market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the hemophilia B market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the hemophilia B market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of hemophilia B across the seven major markets?
- What is the number of prevalent cases (2018-2034) of hemophilia B by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of hemophilia B by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with hemophilia B across the seven major markets?
- What is the size of the hemophilia B patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of hemophilia B?
- What will be the growth rate of patients across the seven major markets?
Hemophilia B: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for hemophilia B drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hemophilia B market?
- What are the key regulatory events related to the hemophilia B market?
- What is the structure of clinical trial landscape by status related to the hemophilia B market?
- What is the structure of clinical trial landscape by phase related to the hemophilia B market?
- What is the structure of clinical trial landscape by route of administration related to the hemophilia B market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Hemophilia B - Unmet Needs10 Hemophilia B - Key Endpoints of Treatment13. Hemophilia B - Attribute Analysis of Key Marketed and Pipeline Drugs16 Hemophilia B - Recent Events and Inputs From Key Opinion Leaders18 Hemophilia B Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Hemophilia B - Introduction
5 Hemophilia B - Disease Overview
7 Hemophilia B - Epidemiology and Patient Population
8 Hemophilia B - Treatment Algorithm, Guidelines, and Medical Practices
11 Hemophilia B - Marketed Products
12 Hemophilia B - Pipeline Drugs
14. Hemophilia B - Clinical Trial Landscape
15 Hemophilia B - Market Scenario
17 Hemophilia B Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 9.2 Billion |
| Forecasted Market Value ( USD | $ 22.5 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
